Home » Market News » DirectorsTalk Highlights » INTERVIEW: Midatech Pharma PLC loan gives capability to manufacturer on a commercial scale
Midatech pharma

INTERVIEW: Midatech Pharma PLC loan gives capability to manufacturer on a commercial scale

Midatech Pharma PLC (LON: MTPH) CFO Nick Robbins-Cherry joins DirectorsTalk to discuss its Spanish Government Loan Approval. Nick provides some background on the company, explains the Spanish loan application, what a re-industrialisation loan is, what it will be used for and what it means for Midatech’s research and operations.

Midatech Pharma is an R&D company focused on delivering innovative oncology and rare disease products to patients. The Company is developing a range of improved chemo-therapeutics or new immuno-therapeutics, using its three-proprietary platform drug delivery technologies, all of which are in the clinic, specifically:

1. Q-Sphera™ platform: our disruptive polymer microsphere technology used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months.

2. MidaCore™ platform: our leading-edge gold nanoparticle technology used for targeting sites of disease at the nanoscale i.e. chemotherapy – improved and targeted delivery of existing chemotherapeutic agents to tumour sites, as well as ii. immunotherapy – enhanced uptake of new immuno-moieties by immune cells that can then mount an immune attack against cancer cells.

3. MidaSolve platform: our innovative nanosaccharide technology used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumours.

Each of our three technologies are thus focussed on improved bio-delivery and bio-distribution of medicines or agents to areas of the body where they are needed and can exert their actions in an effective, safe and precise manner.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.